Quantcast
Last updated on June 20, 2013 at 1:21 EDT

Latest Hyperuricemia Stories

2008-12-06 11:00:00

- Results Presented at ASH Annual Meeting - SAN FRANCISCO, Dec. 6 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology. The study in adult patients with hematological malignancies at high or potential risk for tumor lysis syndrome (TLS) demonstrated that Elitek(R) (rasburicase) significantly reduced plasma uric acid (PUA) levels compared to allopurinol alone (p=0.0012)....

2008-10-27 09:00:41

EAST BRUNSWICK, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. today announced that data from its pegloticase pivotal clinical studies in treatment-failure gout (TFG) patients was presented at scientific sessions during the annual meeting of the American College of Rheumatology (ACR). Four presentations focused on results from the pegloticase double blind placebo controlled Phase 3 pivotal studies. Data from the interim results of the uncontrolled open label...

2008-10-27 09:00:41

Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that preliminary data were presented from an ongoing Phase 1 trial of RDEA594, its lead product candidate in development for the treatment of hyperuricemia and gout, at the 2008 American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in San Francisco, California. Preliminary data from a Phase 1 single ascending dose study of RDEA594 in healthy volunteers show that oral...

2008-09-22 09:00:58

EAST BRUNSWICK, N.J., Sept. 22, 2008 (GLOBE NEWSWIRE) -- Savient Pharmaceuticals, Inc. (Nasdaq:SVNT), announced today that four scientific abstracts on pegloticase and two scientific abstracts based on Treatment Failure Gout (TFG) will be presented at the American College of Rheumatology (ACR) 72nd Annual Scientific Meeting in San Francisco from October 24 - 29, 2008. For complete information on all six abstracts, please visit the ACR website at www.rheumatology.org. About the Phase 3 Study...

2008-09-03 06:00:25

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that treatment with ARCALYST(R) (rilonacept), also known as IL-1 Trap, in a Phase 2 study of gout patients initiating therapy with allopurinol to lower their uric acid levels, produced a statistically significant reduction versus placebo in the incidence of gout flares. In this 83-patient, double-blind, placebo-controlled study, the mean number of flares per patient over the first 12 weeks of urate-lowering therapy was 0.79 with...

2008-08-21 09:01:14

SAN DIEGO, Aug. 21 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has authorized a Phase 1 study evaluating RDEA594 in normal healthy volunteers. RDEA594 is the Company's lead product candidate for the treatment of gout. "Regulatory clearance for us to proceed with our Phase 1 study of RDEA594, within six months from designation as a clinical candidate is a testament to the...

2008-08-04 09:01:05

WILLIAMSVILLE, N.Y., Aug. 4 /PRNewswire/ -- Hamburgers, soft drinks and beer are the staples of summer barbecues across America. However, these foods may cause dangerous changes in your body that can lead to a long list of diseases. The cause? A chemical called uric acid. Uric acid does not come from industrial waste or from excessively processed food. Uric acid is a natural byproduct of your body's metabolism that can build up in your body and lead to heart disease, kidney failure, liver...

2008-07-09 09:01:01

SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. today announced that it has received regulatory approval to begin a Phase 2a proof-of-concept clinical trial evaluating RDEA806 in gout patients with hyperuricemia. Gout, also known as metabolic arthritis, is a painful and debilitating disease caused by abnormally elevated levels of uric acid in the blood stream, and is the most common form of inflammatory arthritis in men over 40. The Company also announced that gout...

997b11bc44c431806c10abfe8bd8b08f
2008-02-01 12:25:00

A British study showed men who consume two or more sugary soft drinks per day increase their risk of gout by 85% compared with those who consume less than one drink per month. The researchers advise those with gout to eliminate sugary drinks from their diets.Gout is a painful joint disease caused when uric acid crystallizes out of the blood into the joints. Symptoms can include painful and swollen joints, mainly in the lower limbs. About 1.5% of the British population suffers from gout, and...


Latest Hyperuricemia Reference Libraries

45_cf9ebc73b3f1a13d4b11b52db1780092
2008-05-22 12:47:07

The Dalmatian is a coach dog which is easily recognized for its unique spotted coat. This ancient breed has been used as a guard dog, bird dog, trail hound, retriever, and most importantly a coach or carriage dog. The Dalmatian was once used to run in attendance on a coach. This ability was eventually transferred to its career as a firehouse dog. The Dalmatian once ran in front of horse-drawn fire carts to help clear a path for them as well as guide them to fires. The Dalmatian is a...

More Articles (1 articles) »